SMURF2 and breast carcinoma: To further corroborate our findings on altered SMURF2 biodistribution in BRCAs, we prepared the cytoplasmic and nuclear fractions from several breast carcinoma cell models, derived from patients’ metastatic sites: MDA-MB-231, MDA-MB-468 and MCF7 cells, and compared SMURF2 localization in these cells to mammary epithelial MCF10A cells.